BridgeBio Pharma (BBIO) Net Cash Flow Growth (5y) (2023 - 2026)

BridgeBio Pharma (BBIO) Net Cash Flow Growth (5y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 BridgeBio Pharma 16.41 Bn 15.47 Bn 184.58 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 21.91%
Dec 31, 2025 -52.96%
Sep 30, 2025 9.43%
Jun 30, 2025 24.27%
Mar 31, 2025 -18.71%
Dec 31, 2024 49.57%
Sep 30, 2024 -26.02%
Jun 30, 2024 23.85%
Mar 31, 2024 27.04%
Dec 31, 2023 -20.85%
Sep 30, 2023 47.18%